利妥昔单抗联合CHOP方案对非霍奇金淋巴瘤免疫功能及补体水平的影响

Effect of Rituximab combined with CHOP regimen on immune function and complement level in non-Hodgkin's lymphoma

目的分析利妥昔单抗联合CHOP(cytoxan,hydroxyrubicin,oncovin,perdinsone,CHOP)方案对非霍奇金淋巴瘤免疫功能、补体水平的影响。方法选取2020年3月起至2022年3月河南省肿瘤医院收治的80例非霍奇金淋巴瘤患者,将单独进行CHOP方案治疗的40例作为对照组,将通过CHOP方案与利妥昔单抗相结合治疗的40例作为观察组,比较两组患者补体水平以及免疫功能等指标。结果①观察组治疗后IGA、IGM以及IGG等免疫功能相关指标分别为(1.52±0.14)g/L、(4.01±2.03)g/L及(9.86±2.35)g/L,均低于对照组(P<0.05);②观察组治疗后LDH以及VEGF等血清因子相关指标分别为(62.42±7.63)U/L及(119.80±8.79)ng/L,均低于对照组(P<0.05);③观察组治疗后C4以及C3等血清补体指标均低于对照组(P<0.05);④观察组治疗后Karnofsky评分高于对照组(P<0.05);⑤对照组不良反应整体发生率高于观察组,组间比较差异具有统计学意义(P<0.05);⑥观察组治疗总有效率高于对照组,组间比较差异具有统计学意义(P<0.05)。结论将CHOP方案联合利妥昔单抗应用于非霍奇金淋巴瘤的治疗中,不仅能够改善患者的免疫能力,还能够促进补体水平进一步降低,有较高的安全性。

Objective To analyze the effects of rituximab combined with CHOP regimen on immune function and complement level of non-Hodgkin lymphoma.Methods A total of 80 patients with non-Hodgkin lymphoma admitted to Henan Cancer Hospital from March 2020 to March 2022 were selected.40 patients treated with CHOP alone were selected as control group,and 40 patients treated with CHOP combined with rituximab were selected as the observation group.The complement level and immune function of the two groups were compared.Results①After treatment,IGA,IGM and IGG in observation group were(1.52±0.14)g/L,(4.01±2.03)g/L and(9.86±2.35)g/L,which were lower than those of control group(P<0.05).②After treatment,LDH and VEGF were(62.42±7.63)U/L and(119.80±8.79)ng/L in observation group,which were lower than those of control group(P<0.05).③The serum complement indexes of C4 and C3 in the observation group were lower than those of the control group after treatment(P<0.05);④The Karnofsky score of observation group was higher than that of control group after treatment(P<0.05);⑤The overall incidence of adverse reactions in control group was higher than that of observation group,and the difference between groups was statistically significant(P<0.05);The total effective rate of the observation group was higher than that of the control group,and the difference between the groups was statistically significant(P<0.05).Conclusion CHOP combined with rituximab in the treatment of non-Hodgkin lymphoma can not only improve the immune capacity of patients,but also promote the further reduction of complement level,with high safety.